The success of current cancer therapies is limited by a combination of efficiency and specificity. For improved treatments to be developed, the ability to target tumour cells selectively is essential, allowing a greater dose of therapeutic agent to be delivered without adversely affecting non-malignant tissue. A novel strategy using the chick anaemia virus protein apoptin, presented in this issue of Gene Therapy, may provide a means to achieve this goal. 1 The development of cancerous tumours results from a combination of increased cell proliferation and an inability to undergo apoptotic cell death. 2, 3 Apoptosis is a complex process which can occur via several pathways, each involving a cascade of events. In general, apoptosis induced by external stimuli such as DNA damage or virus infection proceeds through a p53-dependent pathway, and is regulated by a number of proteins, most notably those of the Bcl-2 family. Conversely, pathways controlling apoptosis during development of an organism are almost exclusively p53-independent, operating instead through the interaction of 'death' receptors with specific ligands (such as Fas-Fas ligand) and by-passing the control of the Bcl-2 family. Whichever pathway is triggered, cell death results from the activation of caspase proteases which dismantle the cell. In the majority of cancerous cells, mutations in p53 or other regulators of p53-dependent apoptosis can be identified. 4 Presently, treatment of cancerous tumours relies mainly on chemotherapy and/or radiotherapy, both of which cause extensive damage to and ultimately death of non-malignant tissue. Gene therapy is a relatively new approach to cancer therapy, and has yet to achieve its full potential. Numerous gene therapy strategies are being developed (reviewed in 5), including delivery of suicide genes such as herpes simplex virus thymidine kinase (HSV TK), apoptosis inducers such as p53 and Bcl-2, and immunostimulatory molecules such as granulocyte/macrophage colony stimulating factor (GMCSF) and interleukin 2 (IL-2). Attempts to refine these strategies to target cancerous cells specifically have concentrated on delivering the vector specifically to tumour cells, on tumour-specific expression of the transgene using tumour-specific promoters, or on local administration of the gene delivery vector. To date, however, the clinical success of these systems is limited by their relatively low efficiency, or by their lack of specificity. 6 The success of cancer therapies, even the more promising gene therapy approaches, is limited further by the p53 status of the cell. 7 Due to its apoptosis-inducing properties, the p53 protein serves a pivotal role in the balance between life and death of a cell. Many cancer therapies, including recent gene therapy strategies as well as the more conventional chemotherapy and radiotherapy approaches, function through p53-dependent mechanisms. Since many cancerous cells are deficient or defective in p53, resistance to anti-tumour therapy is a significant obstacle to successful treatment. Furthermore, delivery of p53 is only clinically beneficial in those cancerous cells which lack functional p53, and has little effect in tumour cells expressing wild type protein. The complex pathway of intracellular events with which p53 is involved means that Bcl-2 status, and that of other apoptosis regulators, can also affect cellular susceptibility to cancer therapies.
A novel gene therapy strategy, involving delivery of the chick anaemia virus (CAV) protein apoptin, may provide a means to overcoming many of these obstacles. Apoptin is the product of the chick anaemia virus VP3 gene. The protein was shown to cause apoptosis in chicken lymphoblastoid cells, 8 but further studies have revealed its remarkable ability to induce apoptosis only in cells which are malignant or transformed, whilst having no apoptosis-inducing properties in normal cells. 9 While this property alone would make apoptin an attractive candidate for cancer gene therapy, the discovery that it induces apoptosis independently of p53, and irrespective of the Bcl-2 or Bax status of the target cells, 10 gives this strategy the potential to surpass all other current cancer gene therapy approaches.
The unique properties of apoptin are thought to depend on its cellular localisation. In normal cells apoptin is found cytoplasmically, whereas in tumour cells it migrates to the nucleus. 9 Here, it may interfere with the supercoiled structure of nuclear chromatin, resulting in DNA condensation and fragmentation, or it may act as a transcriptional regulator, resulting in the induction of genes mediating apoptosis. The lack of p53-dependence of apoptin function suggests that if it does act as a transcriptional regulator, it must do so via a p53-independent cellular apoptosis pathway. One candidate may be the Fas-Fas ligand pathway, which has also been shown to induce apoptosis independently of p53.
In this issue of Gene Therapy, the Noteborn group follow up their promising earlier work with a report describing the successful in vivo administration of apoptin. 1 Using a recombinant adenovirus vector expressing apoptin, apoptosis was induced specifically in a variety of tumour cells in vitro. Significantly, substantial regression of a xenogeneic tumour was demonstrated in vivo following delivery of the adenovirus-apoptin recombinant in a single intratumoural injection. As already proven for other cancer gene therapy systems, repeated injections of the adenovirus-apoptin vector may lead to an even greater antitumour response, and further studies are required to address this, as well as the potency of the apoptin system in other tumour cell types. Repeated in vivo administration of the virus was shown to be well tolerated, suggesting the suitability of this approach for clinical application, and highlighting the potential of an adenovirus vector expressing apoptin for the treatment of solid phase tumours.
In summary, the unique properties of apoptin suggest that it may be able to circumvent the present requirement for vector targeting or promoter-specific expression; its intrinsic tumour-specific function providing sufficient targeting. Furthermore, its potential ability to induce apoptosis in all tumour cells, irrespective of their p53 or Bcl-2 status, gives it an advantage over most other cancer therapies.
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